RPTOR
Basic information
Region (hg38): 17:80544819-80966371
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the RPTOR gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 9 | |||||
missense | 35 | 36 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 1 | |||||
Total | 0 | 0 | 35 | 4 | 7 |
Variants in RPTOR
This is a list of pathogenic ClinVar variants found in the RPTOR region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-80643745-C-G | not specified | Uncertain significance (Dec 21, 2023) | ||
17-80754019-A-G | not specified | Uncertain significance (Aug 10, 2021) | ||
17-80754115-A-G | not specified | Uncertain significance (Jan 26, 2022) | ||
17-80822218-A-G | not specified | Uncertain significance (Jul 28, 2021) | ||
17-80822229-A-G | not specified | Uncertain significance (Jun 29, 2023) | ||
17-80823169-A-G | not specified | Uncertain significance (Aug 30, 2021) | ||
17-80837969-C-T | not specified | Uncertain significance (Sep 25, 2023) | ||
17-80837970-G-A | Benign (Dec 31, 2019) | |||
17-80846530-G-A | not specified | Uncertain significance (Aug 04, 2021) | ||
17-80857839-C-T | not specified | Uncertain significance (Aug 10, 2021) | ||
17-80857845-G-A | not specified | Uncertain significance (Dec 17, 2023) | ||
17-80880473-C-T | not specified | Uncertain significance (Dec 27, 2022) | ||
17-80883428-C-A | Likely benign (Jul 01, 2023) | |||
17-80883477-C-T | not specified | Uncertain significance (Feb 06, 2024) | ||
17-80883478-G-A | Benign (Jul 11, 2018) | |||
17-80883849-G-T | Likely benign (Apr 24, 2018) | |||
17-80883927-C-T | Benign (Jul 11, 2018) | |||
17-80883970-G-A | not specified | Uncertain significance (Mar 11, 2024) | ||
17-80885016-C-T | Benign (Jul 22, 2018) | |||
17-80885134-C-G | not specified | Uncertain significance (Apr 13, 2022) | ||
17-80885147-A-T | not specified | Uncertain significance (Apr 25, 2023) | ||
17-80891747-G-A | not specified | Uncertain significance (Jan 07, 2022) | ||
17-80891750-G-T | not specified | Uncertain significance (Oct 22, 2021) | ||
17-80893744-C-A | not specified | Uncertain significance (Apr 15, 2024) | ||
17-80893793-C-T | not specified | Likely benign (Feb 13, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
RPTOR | protein_coding | protein_coding | ENST00000306801 | 34 | 421553 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 8.31e-11 | 125742 | 0 | 6 | 125748 | 0.0000239 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.94 | 473 | 887 | 0.533 | 0.0000608 | 8741 |
Missense in Polyphen | 91 | 301.45 | 0.30187 | 2909 | ||
Synonymous | -0.175 | 391 | 387 | 1.01 | 0.0000309 | 2618 |
Loss of Function | 7.81 | 3 | 76.8 | 0.0390 | 0.00000406 | 794 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000638 | 0.0000615 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000562 | 0.0000544 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000352 | 0.0000352 |
Middle Eastern | 0.0000562 | 0.0000544 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in the control of the mammalian target of rapamycin complex 1 (mTORC1) activity which regulates cell growth and survival, and autophagy in response to nutrient and hormonal signals; functions as a scaffold for recruiting mTORC1 substrates. mTORC1 is activated in response to growth factors or amino acids. Growth factor-stimulated mTORC1 activation involves a AKT1- mediated phosphorylation of TSC1-TSC2, which leads to the activation of the RHEB GTPase that potently activates the protein kinase activity of mTORC1. Amino acid-signaling to mTORC1 requires its relocalization to the lysosomes mediated by the Ragulator complex and the Rag GTPases. Activated mTORC1 up-regulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. mTORC1 phosphorylates EIF4EBP1 and releases it from inhibiting the elongation initiation factor 4E (eiF4E). mTORC1 phosphorylates and activates S6K1 at 'Thr-389', which then promotes protein synthesis by phosphorylating PDCD4 and targeting it for degradation. Involved in ciliogenesis. {ECO:0000269|PubMed:12150925, ECO:0000269|PubMed:12150926, ECO:0000269|PubMed:23727834}.;
- Pathway
- PI3K-Akt signaling pathway - Homo sapiens (human);mTOR signaling pathway - Homo sapiens (human);Longevity regulating pathway - multiple species - Homo sapiens (human);Autophagy - animal - Homo sapiens (human);Autophagy - other - Homo sapiens (human);AMPK signaling pathway - Homo sapiens (human);Thermogenesis - Homo sapiens (human);Longevity regulating pathway - Homo sapiens (human);MicroRNAs in cancer - Homo sapiens (human);Insulin signaling pathway - Homo sapiens (human);AMP-activated Protein Kinase (AMPK) Signaling;Target Of Rapamycin (TOR) Signaling;PI3K-AKT-mTOR signaling pathway and therapeutic opportunities;Angiopoietin Like Protein 8 Regulatory Pathway;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;Steatosis AOP;Pathways in clear cell renal cell carcinoma;PI3K-Akt Signaling Pathway;Interferon type I signaling pathways;Signal Transduction;Gene expression (Transcription);HSF1-dependent transactivation;Generic Transcription Pathway;Cellular responses to stress;RNA Polymerase II Transcription;mTORC1-mediated signalling;Energy dependent regulation of mTOR by LKB1-AMPK;mTOR signalling;insulin Mam;TP53 Regulates Metabolic Genes;Macroautophagy;Cellular responses to external stimuli;Regulation of PTEN gene transcription;PTEN Regulation;PIP3 activates AKT signaling;Cellular response to heat stress;Transcriptional Regulation by TP53;Intracellular signaling by second messengers;mTOR signaling pathway;Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met);LKB1 signaling events;insulin
(Consensus)
Intolerance Scores
- loftool
- 0.0334
- rvis_EVS
- -2.58
- rvis_percentile_EVS
- 0.83
Haploinsufficiency Scores
- pHI
- hipred
- Y
- hipred_score
- 0.825
- ghis
- 0.562
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.860
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Rptor
- Phenotype
- embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; hematopoietic system phenotype; digestive/alimentary phenotype; immune system phenotype; skeleton phenotype; growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); muscle phenotype; cellular phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- regulation of cell growth;positive regulation of endothelial cell proliferation;cell cycle arrest;regulation of cell size;cellular response to starvation;positive regulation of peptidyl-threonine phosphorylation;viral process;regulation of macroautophagy;positive regulation of cell growth;cellular response to nutrient levels;TOR signaling;positive regulation of TOR signaling;activation of protein kinase activity;positive regulation of peptidyl-serine phosphorylation;TORC1 signaling;positive regulation of transcription by RNA polymerase III;cellular response to amino acid stimulus;cellular response to leucine;negative regulation of protein serine/threonine kinase activity;positive regulation of protein serine/threonine kinase activity;regulation of cellular response to heat;positive regulation of G1/S transition of mitotic cell cycle
- Cellular component
- nucleoplasm;cytoplasm;lysosome;lysosomal membrane;cytosol;cytoplasmic stress granule;dendrite;TORC1 complex;neuronal cell body
- Molecular function
- RNA polymerase III type 1 promoter DNA binding;RNA polymerase III type 2 promoter DNA binding;RNA polymerase III type 3 promoter DNA binding;TFIIIC-class transcription factor complex binding;protein binding;protein kinase binding;protein serine/threonine kinase inhibitor activity;protein kinase activator activity;protein binding, bridging;protein-containing complex binding;14-3-3 protein binding